CPT® Code 90378

1. Indications

The RSV monoclonal antibody is indicated for use in specific high-risk populations to provide protection against respiratory syncytial virus infections. The following conditions and circumstances warrant the administration of this immunizing agent:

• Premature Infants Infants born prematurely are at a higher risk for severe RSV disease due to their underdeveloped lungs and immune systems.
• Infants with Pulmonary Conditions Infants who have existing conditions that affect their pulmonary function, such as chronic lung disease, are more susceptible to complications from RSV infections.
• Infants with Congenital Heart Disease Those with congenital heart defects may have compromised cardiovascular and respiratory systems, making them particularly vulnerable to the effects of RSV.

2. Procedure

The administration of the RSV monoclonal antibody involves several key procedural steps to ensure safety and efficacy:

• Step 1: Patient Assessment Prior to administration, a thorough assessment of the infant's medical history and current health status is conducted to confirm eligibility for the monoclonal antibody treatment. This includes evaluating the infant's weight, as the dosage is weight-dependent.
• Step 2: Preparation of the Medication The RSV monoclonal antibody is prepared for administration by drawing the appropriate dosage based on the infant's weight. Each dose is typically 50 mg, and the preparation must be done in a sterile environment to prevent contamination.
• Step 3: Administration The prepared monoclonal antibody is administered via intramuscular injection, typically in the thigh muscle. Care is taken to ensure proper technique to minimize discomfort and ensure effective delivery of the medication.
• Step 4: Post-Administration Monitoring After the injection, the infant is monitored for any immediate adverse reactions or side effects. This monitoring is crucial to ensure the safety of the patient following the administration of the monoclonal antibody.

3. Post-Procedure

Following the administration of the RSV monoclonal antibody, it is important to observe the infant for any potential side effects or adverse reactions. Commonly, the infant may experience mild discomfort at the injection site, which typically resolves quickly. Parents or caregivers should be informed about signs of allergic reactions or other complications that may require immediate medical attention. The administration of the monoclonal antibody is generally repeated on a monthly basis during the RSV season, and ongoing assessments of the infant's health and risk factors should be conducted to determine the need for continued treatment. Documentation of each administration, including the dosage and any observed reactions, is essential for compliance and billing purposes.